Additional speaker information is forthcoming. Click on a name below to jump to a particular speaker.
Dr. Örn Almarsson
Senior Vice President and Head of Formulation
Dr. Örn Almarsson brings to his role as Co-Head Delivery Sciences at Moderna more than 20 years of experience in pharmaceuticals and biotechnology. Over the course of his career, he has worked on translation of drug candidates from discovery into development through studies of pharmaceutical materials science and drug delivery applications. Prior to joining Moderna, Dr. Almarsson held positions of increasing responsibility in pharmaceutical R&D at Merck, TransForm Pharmaceuticals/J&J PRD and Alkermes. Dr. Almarsson received his B.Sc. in chemistry from the University of Iceland and Ph.D. in bio-organic chemistry from the University of California at Santa Barbara. Prior to joining industry, he held a post-doctoral position in biotechnology with Prof. Alexander Klibanov at MIT.
Dr. Daniel Anderson
Samuel A Goldblith Professor of Applied Biology, Chemical Engineering and Health Sciences and Technology
Professor Daniel G. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances and products in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 400 papers, patents and patent applications. These patents were the basis for the foundation of a number of companies in the pharmaceutical, biotechnology, and consumer products space, and have led to a number of products that have been commercialized or are in clinical development.
Dr. Tatiana Bronich
Professor & Co-Director, Center for Drug Delivery and Nanomedicine
Department of Pharmaceutical Sciences, College of Pharmacy
University of Nebraska Medical Center, Durham Research Center
In the professional program, Dr. Bronich lectures in the Pharmaceutical Biotechnology course where she utilizes her expertise in the area of gene therapy. At the graduate level, Dr. Bronich is a co-coordinator and lecturer for the Polymer Therapeutics course, and also teaches in the Quantitative Pharmaceutical Analysis course. Dr. Bronich’s research interests are in the area of self-assembling polymer materials and applications of these materials in medicine. Of special interest is the design and study of novel types of functional materials based on complexes formed between block ionomers and oppositely charged polymers and low molecular weight amphiphilic molecules. These systems are of great fundamental importance as models of biological systems formed as a result of self-assembly processes. In addition, her recent work has expanded to include the application of these amphiphilic block copolymers and block ionomer complexes in drug delivery to treat cancer and the development of the polycation-DNA complexes for gene delivery.
↑ Return to Top
Dr. Yizhou Dong
Asst Professor, Pharm CBO/Coll;
Asst Professor, Radiation Oncology
Ohio State University
Yizhou Dong received his B.S. from Peking University, Health Science Center (2002) and M.S. from Shanghai Institute of Organic Chemistry (2005). In 2009, he received his Ph.D. in pharmaceutical sciences from the University of North Carolina at Chapel Hill under the supervision of Professor K.-H. Lee. From 2010 to 2014, he was a postdoctoral fellow in the laboratory of Professors Robert Langer and Daniel Anderson at MIT. Dr. Dong joined OSU College of Pharmacy as an Assistant Professor in 2014, and was promoted to Associate Professor in 2018. His research focuses on the design and development of nanotechnology platforms for the treatment of genetic disorders, infectious diseases, and cancers. Dr. Dong has authored over fifty papers and patents. Several of his inventions have been licensed and are currently under development as drug candidates for clinical trials. He is the recipient of numerous honors, including Early Career Investigator Award from the Bayer Hemophilia Awards Program, Research Awards from the National PKU Alliance, New Investigator Grant from the AAPS Foundation, Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences (NIGMS), and 2017 Ohio State Early Career Innovator of the Year.
↑ Return to Top
Dr. Laird Forrest
Laird Forrest is a Professor of Pharmaceutical Chemistry at the University of Kansas. He received his BS in Chemical Engineering at Auburn and his MS and PhDs in Chemical and Bimolecular Engineering at the University of Illinois in Urbana-Champaign, followed by a post-doc at Wisconsin. His group focuses on drug formulation and pharmacokinetics, with a special interest in the application of localized therapeutics in the treatment of cancers.
↑ Return to Top
Dr. Jinming Gao
Jinming Gao received BSc in Chemistry from Peking University in 1991. He carried out graduate studies under George M. Whitesides at Harvard and received a PhD in Physical Organic Chemistry in 1996. Following PhD, he completed postdoctoral training in Biomedical Engineering under Robert S. Langer at MIT. In 1998, Dr. Gao joined the faculty of Biomedical Engineering at Case Western Reserve University. He was promoted to Associate Professor with tenure in 2004. In 2005, Dr. Gao moved his lab to UT Southwestern, where he is currently a Professor of Oncology, Pharmacology and Otolaryngology. Dr. Gao’s lab pioneers the understanding and implementation of molecular cooperativity principles to improve the precision of medicine. The lab-invented pH threshold sensor technology is currently in Phase I clinical trials for image-guided cancer surgery. Dr. Gao has served as the past chair of the Gene and Drug Delivery study section, and is currently a member of the advisory council to the Center for Scientific Review at the National Institutes of Health.
Dr. Hamid Ghandehari
Professor, Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah
Director of Utah Center for Nanomedicine
Co-Founder and Co-Director of the Nano Institute of Utah
Director of the University of Utah Nanotechnology Training Program.
Hamid Ghandehari is a Professor at the Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, Director of Utah Center for Nanomedicine and Co‐Founder and Co‐Director of the Nano Institute of Utah at the University of Utah. His research focuses on the design of recombinant polymers for gene and drug delivery, targeted delivery of polymer therapeutics to solid tumors, oral delivery of chemotherapeutics, and assessing the biocompatibility of silica and dendritic nanoconstructs. Dr. Ghandehari is Editor in Chief of Advanced Drug Delivery Reviews, Fellow of the American Institute for Medical and Biological Engineering, the American Association of Pharmaceutical Scientists and the Controlled Release Society. He serves on the scientific advisory boards of several national and international drug delivery organizations such as the Controlled Release Society. He has published over 175 articles, and given over 230 invited talks. He received his BS in Pharmacy and PhD in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah.
Dr. Joe Gray
Professor and Gordon Moore Endowed Chair, Dept of Biomedical Engineering;
Director, OHSU Center for Spatial Systems Biomedicine;
Associate Director for Biophysical Oncology, Knight Cancer Institute
Dr. Joe W. Gray is the Director, OHSU Center for Spatial Systems Biomedicine; and Associate Director for Biophysical Oncology, Knight Cancer Institute. He applies ‘omic and imaging technologies to elucidate mechanisms by which cancers become resistant to treatment and uses this information to develop therapeutic strategies to more durably control advanced cancers. He also serves on the Board of Counselors for the Radiation Effects Research Foundation. He has more than 500 publications and 80 US patents. Major awards include the E.O. Lawrence Award, U.S. Department of Energy; Curt Stern Award, ASHG; the Alfred G. Knudson Award in Cancer Genetics, NCI, election as a Fellow of the American Association for Cancer Research and National Academy of Medicine.
↑ Return to Top
Dr. Markus Grompe
Professor of Pediatrics School of Medicine
Ray Hickey Chair of the of Pape’ Family Pediatric Research Institute, Pediatrics School of Medicine
Molecular and Medical Genetics Graduate Program, School of Medicine
Cancer Biology Graduate Program, School of Medicine
Program in Molecular and Cellular Biosciences, School of Medicine
Dr. Markus Grompe is a Professor at the Papé Family Pediatric Research Institute at Oregon Health & Science University in Portland, Oregon, USA. He is a physician-scientist who is clinically active as a biochemical geneticist. Dr. Grompe is scientific founder of two biotechnology companies, Yecuris Corporation (Tigard) and Ambys Medicines (Redwood, CA). His research covers three major topics: 1) Cell and gene therapy for genetic liver diseases; 2) Fanconi’s Anemia and 3) beta-cell replacement therapy for diabetes. For hepatic disorders his lab has focused on in vivoselection to enhance gene and cell transplantation therapy. Recently, he has worked on therapeutic gene editing of hepatocytes in vivo. He developed and commercialized the FRG mouse for the extensive replacement of the liver by human hepatocytes. His lab clonedFANCD2, the lynchpin protein of the Fanconi Anemia DNA repair pathway and developed novel small molecule therapy for this disease. In the diabetes field his lab is known for developing monoclonal antibodies for the viable isolation of all major human pancreatic cell types. Recently, his lab showed that human pancreatic beta-cells exist as four distinct subtypes. He has published over 200 peer-reviewed articles and holds numerous patents.
↑ Return to Top
Dr. Paulina Hill
Principal Healthcare Investor
Polaris Venture Capital
Dr. Paulina Hill joined Polaris in 2012 and focuses on investments in healthcare from the Boston office. Paulina serves on the boards of Arsenal Medical, Faraday Pharmaceuticals, Kala Pharmaceuticals (NASDAQ:KALA), KinDex Pharmaceuticals and Neuronetics (NASDAQ: STIM). She is an observer on the boards of Microchips Biotech and Sofregen. In addition to her investing role, Paulina served as the founding CEO of Polaris-backed CAMP4, a biotech startup based in Cambridge, MA. She also serves on the board of The Capital Network, a non-profit that provides fundraising education to startup entrepreneurs and is a mentor for the Canadian Technology Accelerator. Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at MIT in Robert Langer’s lab. Paulina is the founding President of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee. Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. ECU honored Paulina with the Incredible Women’s award in 2017.
↑ Return to Top
Dr. Jesse Jokerst
Asst Professor, Dept of Nanoengineering
Jesse V. Jokerst is an Assistant Professor in the Department of NanoEngineering at UC San Diego. Dr. Jokerst graduated cum laude from Truman State University (Kirksville, Missouri) in 2003 with a B.S. in Chemistry and completed a Ph.D. in Chemistry at The University of Texas at Austin in 2009 with John T. McDevitt. Jesse was a postdoc with Sam Gambhir at Stanford Radiology from 2009-2013 and was an Instructor in that same department from 2013-2015. At Stanford, Jesse received a prestigious American Cancer Society Postdoctoral Fellowship, a Burroughs Wellcome Collaborative Research Training Grant, and an NIH R25 Postdoctoral Fellowship. Jesse started at UCSD in July of 2015, and his research focuses on novel chemical probes as acoustic contrast agents. He is currently funded under the NIH’s K99/R00 Pathway to Independence and New Innovator Awards.
↑ Return to Top
Dr. Alexander Kabanov
Director, Center for Nanotechnology inDrug Deliver;
Mescal S Ferguson Distinguished Professor;
Co-Director Carolina Institute for Nanomedicine;
Adjunct Professor of Biomedical Engineering
Born March 27, 1962 in Moscow. Graduated from M. V. Lomonosov Moscow State University (MSU) in 1984, where also received Ph.D. in 1987 and D.Sc. in 1990. Scientific career has started in Soviet Union and continued in United States first, in the University of Nebraska Medical Center (UNMC), Omaha, Nebraska (1994-2012) where he founded the first academic nanomedicine center in the United States (2004-), and then in the University of North Carolina at Chapel Hill (2012-), where he is a Mescal S. Ferguson Distinguished Professor, Director, Center for Nanotechnology in Drug Delivery, and Carolina Institute for Nanomedicine. Conducted research that introduced polymeric micelles, DNA/polycation complexes (polyplexes), block ionomer complexes, nanogels, nanoparticle-macrophage carriers and exosomes for delivery of small drugs, nucleic acids and polypeptides to treat cancers and diseases of the central nervous system. Co-invented the first polymeric micelle drug to enter clinical trials. Published over 300 scientific papers, cited over 31,000 times (Hirsh index 94). Named the Thomson Reuters 2014 Highly Cited Researcher. Trained over 65 graduate students and postdocs. Cumulative research support has been over $115 M in grants and over $60 M in private investment and industry-sponsored R&D funding. Holds 34 US patents and co-founded several companies, most recently, SoftKemo/BendaRx, Ostrea and delAQUA. Founded the first nanomedicine symposium series in the United States, NanoDDS, chaired/co-chaired two Gordon Research Conferences. Elected member of Academia Europaea (MAE) and a fellow of NAI, CRS and AIMBE, among other distinctions. A recipient of a Russian Megagrant and professor at MSU where he has established a laboratory with the megagrant support in 2010.
Dr. Ali Khademhosseini
Professor, Dept of Bioengineering, Dept of Radiology, Dept of Chemical and Biomolecular Engineering
Director of Center for Minimally Invasive Therapeutics (C-MIT)
His research is based on developing micro- and nanoscale biomaterials to control cellular behavior with particular emphasis in developing engineered materials and systems for tissue engineering. He is also developing ‘organ-on-a-chip’ systems that aim to mimic human response to various chemicals in vitro. In addition, his laboratory is developing technologies to control the formation of vascularized tissues with appropriate microarchitectures as well as regulating stem cell differentiation within microengineered systems. He has also pioneered various high performance biomaterials for medical applications that are currently being pursued for clinical translation.
↑ Return to Top
Dr. Glen Kwon
University of Wisconsin
Dr. Glen S. Kwon is the Jens T. Carstensen Professor in the School of Pharmacy at the University of Wisconsin. He received a B.S. in Chemistry in 1986 and Ph.D. in Pharmaceutics in 1991 from the University of Utah. He was a Japan Society for the Promotion of Science Postdoctoral Fellow at the Institute of Advanced Biomedical Engineering and Science at Tokyo Women’s Medical University in Tokyo, Japan from 1991 to 1993 and an Assistant Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta in Edmonton, Canada from 1993 to 1997. He received the Jorge Heller Journal of Controlled Release/Controlled Release Society (CRS) Outstanding Paper Award in 1994 and the CRS Young Investigator Research Achievement Award in 2003. He was elected a Fellow of the American Association of Pharmaceutical Scientists in 2012. He was selected as a highly-cited researcher by Thomson Reuters in the category of Pharmacology & Toxicology in 2014. He is co-founder of Co-D Therapeutics Inc., a start-up company developing taxane-based nanomedicines. He serves on editorial boards of J. Controlled Release, Molecular Pharmaceutics, and Pharm. Res. His research focuses on pharmaceutical nanotechnology for drug, gene and peptide/protein-based therapeutics.
↑ Return to Top
Dr. Gabriel Kwong
Assistant Professor, Wallace H Coulter, Department of Biomedical Engineering
Dr. Kwong is an Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech School of Engineering and Emory School of Medicine. As director of the Laboratory for Synthetic Immunity (lsi.gatech.edu), Dr. Kwong leads a multidisciplinary research team dedicated to advancing human health by merging engineering approaches with discoveries in immunology. Dr. Kwong earned his B.S. in Bioengineering from UC Berkeley, his Ph.D. from Caltech, and conducted postdoctoral studies at MIT. In recognition of his work, Dr. Kwong was named a “Future Leader in Cancer Research and Translational Medicine” by the Massachusetts General Hospital, and selected by the National Academy of Engineering to the US Frontiers of Engineering. He is recipient of the NIH Ruth L. Kirschstein National Research Service Award, Burroughs Wellcome Fund Career Award at the Scientific Interface, and the NIH Director’s New Innovator Award. He is co-founder and Chief Scientific Officer (CSO) of Glympse Bio, which is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. Dr. Kwong holds 11 issued or pending patents in biotechnology.
↑ Return to Top
Dr. Martin Maier
Dr. Maier joined Alnylam in 2006 where he currently serves as Vice President, Research heading the RNAi Discovery group and co-leading an interdisciplinary research team focused on RNAi platform technology. In these roles, Dr. Maier has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple programs to development. Martin’s more than 20 years of industrial experience in the field of oligonucleotide therapeutics, include positions at Ionis Pharmaceuticals, most recently as an Associate Director and Group Leader in the Medicinal Chemistry department. He is the author of more than 70 peer-reviewed scientific publications and inventor on more than 30 issued patents. Martin received his professional degree in Chemistry and his Ph.D. in Organic Chemistry at the University of Tübingen, Germany.
Dr. Tamara Minko
Distinguished Professor Chair, Department of Pharmaceutics
Dr. Tamara Minko, Ph.D. is a Distinguished Professor and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey and member of the Cancer Institute of New Jersey. Dr. Minko’s current research interests include drug, nucleic acid and peptide delivery, nanotechnology, personalized nanomedicine, biopharmaceutics, imaging and molecular targeting. She is an author and co-author of more than 400 publications. Her Hirsch factor is 53 (citations – 13,144). Dr. Minko is a President of Controlled Release Society – CRS (2017-2018), an elected Fellow of three professional scientific organizations: CRS, American Association of Pharmaceutical Scientists (AAPS), and American Institute for Medical and Biomedical Engineering (AIMBE); recipient of numerous awards, Executive Editor of Advanced Drug Delivery Reviews, Editor of Pharmaceutical Research, member of editorial board of more than ten scientific journals. She was a Co-organizer of NANODDS-2012. Her research is supported by grants from NIH, NSF, DOD and other national and international sources.
↑ Return to Top
Dr. Suzie Pun
Associate Professor, Department of Bioengineering
University of Washington
Suzie H. Pun is the Robert F Rushmer Professor of Bioengineering, an Adjunct Professor of Chemical Engineering, and a member of the Molecular Engineering and Sciences Institute at UW. She is a fellow of the National Academy of Inventors (NAI) and American Institute of Medical and Biological Engineering (AIMBE), and has been recognized with MIT Technology Review’s “Top 100 Young Innovators” designation, the Presidential Early Career Award for Scientists and Engineers in 2006, the 2014 Young Investigator Award from the Controlled Release Society, and as an AAAS-Lemelson Invention Ambassador in 2015. She serves as an Associate Editor for ACS Biomaterials Science and Engineering. Her research focus area is in biomaterials and drug delivery.
Suzie Pun received her B.S. in Chemical Engineering from Stanford University and her Ph.D. in Chemical Engineering from the California Institute of Technology. She also worked as a senior scientist at Insert Therapeutics/Calando Pharmaceuticals developing polymeric drug delivery systems before joining the Department of Bioengineering at University of Washington.
Dr. Jianghong Rao
Professor of Radiology (Molecular Imaging Program at Stanford) and Chemistry
Dr. Jianghong Rao received his BS in Chemistry from Peking University in 1991, a MS in chemistry from Rutgers, the State University of New Jersey, New Brunswick in 1994, and a PhD in Chemistry from Harvard University in 1999. After completing a Damon Runyon Cancer Research Foundation postdoctoral fellowship at UCSD with Professor Roger Y. Tsien in 2001, he joined the faculty of the Department of Molecular and Medical Pharmacology at UCLA as assistant professor. In 2004, he moved to Stanford University where he is currently a full Professor of Radiology and Chemistry (By courtesy). His general research interest is focused on developing new imaging strategies, molecular probes and nanoparticles to interrogate biological and medical problems.
↑ Return to Top
Dr. Jan Schnitzer
Dr Jan E. Schnitzer, M.D. is the Institute Director of Proteomics Research Institute of System Medicine (PRISM) which was founded in 2009 by Dr. Schnitzer, a world-renowned expert in vascular biology with almost four decades of research experience. Upon earning his MD in 1985 from the University of Pittsburgh, he served as a Post-Doctoral Fellow in the Department of Cell Biology, Yale University Medical School, where he began his pioneering work on the caveolae transcytosis transport pathway. He served as Scientific Director for the Sidney Kimmel Cancer Center, San Diego, CA, from 1999-2009 prior to founding PRISM.
Dr. Schnitzer has received many awards, including the Established Investigator Award from the American Heart Association, the CaP Cure Award in Cancer, and the Kleinerman Lectureship Award for Pulmonary Pathobiology. Over the last two decades, he has served as Associate Editor of several journals and on the Scientific Advisory Board of several companies. He is the recipient of several multi-million dollar NIH grants and has led pioneering projects in the fields of vascular biology and cancer research.
Dr. Avi Schroeder
Professor, Chemical Engineering
Technion Israel Institute of Technology
Avi Schroeder is an Assistant Professor of Chemical Engineering at the Technion – Israel Institute of Technology where he heads the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies which focuses on developing nanotechnologies for precision medicine (https://www.schroederlab.com/). Dr. Schroeder conducted his Postdoctoral studies at the Massachusetts Institute of Technology, and his PhD at the Hebrew and Ben Gurion Universities. Avi is the recipient of more than 25 national and international awards, including named a KAVLI Fellow, a Horev Fellow – Leaders in Science and Technology, an Alon Fellow as well as the Intel Nanotechnology-, TEVA Pharmaceuticals-, and the Wolf Foundation Krill Award. Avi is the author of more than 45 research papers inventor of 17 patents and co-founder of multiple startup companies based on these discoveries.
↑ Return to Top
Dr. Ankur Singh
Assistant Professor, Sibley School of Mechanical and Aerospace Engineering;
Assistant Professor, Meingig School of Biomedical Engineering
Prof. Singh is an Assistant Professor with joint appointments in the Sibley School of Mechanical Engineering and Meinig School of Biomedical Engineering. He is a standing member of the Englander Institute for Precision Medicine at Cornell Medicine (NYC) and has affiliations with Cornell’s Immunology and Infectious Disease Program. He joined Cornell University in 2013, after his postdoctoral training in cell mechanobiology, cell-matrix interactions, and stem cell engineering at Georgia Tech with Prof. Andres Garcia. Prior to that, he received his Ph.D. in Biomedical Engineering at The University of Texas at Austin with Prof. Krishnendu Roy (now at Georgia Tech).
His “Immunotherapy and Cell Engineering” laboratory at Cornell is developing strategies to engineer adaptable, designer immune organoids and enabling technologies for the mechanistic understanding of healthy and diseased immune cells. He has received funding from the National Institute of Health (NIAID, NCI), National Science Foundation, Department of Defense, and the Lymphoma and Leukemia Society, among others. He has published over 41 peer-reviewed journal articles, including those in Nature Methods, Nature Materials, Nature Communications, Cell Reports, PNAS, Blood, Nature Protocols, Biomaterials, and J Controlled Release. He is a recipient of the several scientific awards (including the NSF CAREER, 3M Non-Tenured Faculty Award, and the DoD Career award) and Cornell Engineering Teaching Excellence Award. His immune organoids research has been identified among Top 100 Discoveries of 2015 by the Discover Magazine. Prof. Singh is the Founder and twice elected Chair of the Immune Engineering Special Interest Group (SIG) at the Society for Biomaterials. He currently serves on the editorial board of Science Translational Medicine.
Dr. Arturo Vegas
Assistant Professor, Chemistry
Dr. Arturo J. Vegas is the Peter Paul Career Development Professor at Boston University. He is appointed in the Department of Chemistry, has an affiliation with the Department of Biomedical Engineering, and is a core faculty member of both the BU Center for Molecular Discovery as well as the BU Nanotechnology Innovation Center. He was recently awarded a New Innovator Type 1 Diabetes Pathfinder Award by the NIH.
Arturo’s lab integrates expertise from the areas of organic synthesis, chemical biology, materials science, and biomedical engineering to address challenging problems in drug delivery. The lab is developing novel chemical tools, materials and approaches for targeting therapeutics to diseased tissues and enabling new medical technologies, with therapeutic emphasis on cancer and diabetes. Current areas of focus are immunomodulation of type 1 diabetes, targeting of tumor microenvironments, and the development of new materials with designed and predictable biological properties.
Arturo received his BA in Biology from Cornell University and a PhD in Chemistry from Harvard University. His doctoral studies under the direction of Professor Stuart Schreiber at Harvard focused on developing novel drug-like compounds that modulate chromatin-modifying enzymes, now popular targets for cancer therapeutics. His postdoctoral work with Professors Robert Langer and Daniel G. Anderson at MIT led to the development of new materials for cell encapsulation, cell-based therapies, and nucleic acid delivery. His work has been published in multiple high-impact journals, including Nature Biotechnology and Nature Medicine, and has led to 10 patents both issued and pending.
Dr. Andrew Z. Wang
UNC – Chapel Hill
Andrew Z. Wang, MD, is Associate Professor and Director of Clinical and Translational Research, Department of Radiation Oncology, UNC-Chapel Hill. He is also the co-Director of the Carolina Cancer Nanotechnology T32 training program. Dr. Wang earned his undergraduate degrees from Indiana University and medical degree from the HST program at Harvard Medical School. He completed his radiation oncology training in the Harvard Radiation Oncology Program. Following residency, Dr. Wang joined the UNC faculty in 2009. Dr. Wang’s research program is focused on the clinical translation of engineering sciences, including Nanomedicine, to oncology. His research spans a wide spectrum of translational research, from preclinical research to early phase clinical trials. He also co-founded Capio Biosciences, a biotech startup that is translating a nanotechnology-based circulating tumor cell capture assay.
↑ Return to Top
Dr. Liangfang Zhang
Professor, Department of Nanoengineering, Moores Cancer Center
Dr. Liangfang Zhang received his B.E. and M.S. degrees in Chemical Engineering from Tsinghua University, and his Ph.D. in Chemical & Biomolecular Engineering from the University of Illinois at Urbana-Champaign in 2006 under the supervision of Prof. Steve Granick. He was a postdoctoral associate in the laboratory of Prof. Robert Langer at MIT during 2006-2008. He joined the Department of Nanoengineering at UC San Diego as an Assistant Professor in July 2008 and was promoted to an Associate Professor with tenure in March 2012 and to Professor in July 2014. Dr. Zhang’s research interests focus on biomimetic nanomedicine, with a particular interest in creating and evaluating nanostructured biomaterials for drug delivery, detoxification and vaccination for treatment of infectious diseases and cancer. He has published over 170 peer-reviewed articles and holds 55 issued/pending patents. He received the ACS Victor K. LaMer Award (2009), UCSD Jacobs School of Engineering Best Teacher Award (2011), ACS Unilever Award (2012), MIT Technology Review’s TR35 Innovator Award (2013), AIChE Allan P. Colburn Award (2014), AIMBE Fellow (2015), Popular Science’s Brilliant 10 Award (2016), U.S. Department of State ASPIRE Award (2017), and Kabiller Young Investigator Award (2017).
↑ Return to Top